Abstract
Plasmepsins (PMs) are involved in the degradation of host cell hemoglobin during malaria infection. PM II and IV initiate the degradative process, and have been suggested as attractive targets for treatment of malaria. Previously, 30 compounds were identified by post-processing the results of a large docking screen of commercially available compounds using an automated procedure based on molecular dynamics refinement and binding free-energy estimation using MM-PBSA and MM-GBSA (Degliesposti et al., 2009). Presently, these were experimentally validated using an inhibition assay based on fluorescence resonance energy transfer (FRET) and hemoglobin substrate degradation. Remarkably, 26 of the 30 tested compounds were active as PM II inhibitors, with FRET IC50 values ranging from 4.3 nM to 1.8 μM. Also, IC50 value for PM IV inhibition ranged from 9.34 nM to 83 μM and the best inhibitor among the 30 compounds was compound 7. Hemoglobin degradation by recombinant PM II and IV was completely inhibited by 100 μM of compound 7. The newly identified compounds, and one in particular (compound 7), can inhibit PM II and IV activity and hemoglobin degradation in vitro. These experiments suggest an overall approach in the design of powerful and selective PM II and IV inhibitors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Asojo OA, Afonina E, Gulnik SV, Yu B, Erickson JW, Randad R, Medjahed D, and Silva AM (2002) Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370. Acta Crystallogr. Sect. D Biol. Crystallogr 58: 2001–2008
Banerjee R, Liu J, Beaty W, Pelosof L, Klemba M, and Goldberg DE (2002) Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a prote- ase with an active-site histidine. Proc. Natl Acad. Sci. USA 99: 990–995
Banerjee R, Francis SE, and Goldberg DE (2003) Food vacuole plasmepsins are processed at a conserved site by an acidic convertase activity in Plasmodium falciparum. Mol. Biochem. Parasitol. 129: 157–165
Berry C, Humphreys MJ, Matharu P, Granger R, Horrocks P, Moon RP, Certa U, Ridley RG, Bur D, and Kay J (1999) A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Lett. 447: 149–154
Breman JG (2001) The ears of the hyppopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64: 1–11
Coombs GH, Goldberg DE, Klemba M, Berry C, Kay J, and Mottram JC (2001) Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17: 532–537
Degliesposti G, Kasam V, Costa AD, Kang HK, Kim N, Kim DW, Breton V, Kim D, and Rastelli G (2009) Design and Discovery of Plasmepsin II Inhibitors Using an Automated Workflow on Large-Scale Grids. ChemMedChem 4: 1164–1173
Ersmark K, Samuelsson B, and Hallberg A (2006) Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev. 26: 626-666.
Gagliardi F, Jones B, Grey F, Begin ME, and Heikkurinen M (2005) Building an infrastructure for scientific Grid computing: status and goals of the EGEE project. Philos. Transact. A Math. Phys. Eng. Sci. 363: 1729–1742
Gluzman, IY, Francis SE, Oksman A, Smith CE, Duffin KL, and Goldberg DE (1994) Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J. Clin. Invest. 93: 1602–1608
Greenwood BM, Bojang K, Whitty CJ, and Targett GA (2005) Maraia. Lancet 365:1487–1498
Hill J, Tyas L, Phylip LH, Kay J, Dunn BM, and Berry C (1994) High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett. 352:155–158
Istvan ES, and Goldberg DE (2005) Distal substrate interactions enhance plasmepsin activity. J. Biol. Chem. 280: 6890–6896
Jacq N, Breton V, Chen HY, Ho LY, Hofmann M, Kasam V, Lee HC, Legre Y, Lin SC, Maaβ A, Medernach E, Merelli I, Milanesi L, Rastelli G, Reichstadt M, Salzemann J, Schwichtenberg H, Wu YT, and Zimmermann M (2007) Virtual screening on large scale grids. Parallel Comp. 33: 289–301
Jiang S, Prigge ST, Wei L, Gao Y, Hudson TH, Gerena L, Dame JB, and Kyle DE (2001) New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrob. Agents Chemother. 45:2577–2584
Johansson PO, Chen Y, Belfrage AK, Blackman MJ, Kvarnstrom I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, and Samuelsson B (2004) Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II: Use of solid-phase synthesis to explore novel statine motifs. J. Med. Chem. 47: 3353–3366
Kasam V, Zimmermann M, Maass A, Schwichtenberg H, Wolf A, Jacq N, Breton V, and Hofmann-Apitius M (2007) Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid. J. Chem. Inf. Model. 47:1818–1828
Klemba M, and Goldberg DE (2005) Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum. Mol. Biochem. Parasitol. 143: 183–191
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685
Luker KE, Francis SE, Gluzman IY, and Goldberg DE (1996) Kinetic analysis of plasmepsin I and II aspartic protease of the Plasmodium falciparum digestive vacuole. Mol. Biochem. Parasitol. 79: 71–78
Matayoshi ED, Wang GT, Krafft GA, and Erickson J (1990) Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247: 954–958
May J, and Meyer CG (2003) Chemoresistance in falciparum malaria. TRENDS Parasitol. 19: 432–435
Morishima H, Takita T, Aoyagi T, Takeuchi T, and Umezawa H (1970)The structure of pepstatin. J. Antibiolot. (Tokyo) 23: 259–262
Ridley RG (2002) Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415: 686–693
Sijwali PS, Shenai BR, Gut J, Singh A, and Rosenthal PJ (2001) Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem. J. 360: 481–489
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this paper
Cite this paper
Kang, HK., Hwang, SW., Kim, DW., Breton, V., Kim, D. (2010). In Vitro Test for Potential Inhibitors of Plasmepsin II and IV as Anti-malarial Agents. In: Lin, S., Yen, E. (eds) Managed Grids and Cloud Systems in the Asia-Pacific Research Community. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-6469-4_4
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6469-4_4
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-6468-7
Online ISBN: 978-1-4419-6469-4
eBook Packages: Computer ScienceComputer Science (R0)